C oronary artery bypass graft (CABG) surgery has, until recently, been considered the standard therapy for the treatment of unprotected left main coronary artery (ULM) disease. 1 With continual improvements in stent technology and adjunctive pharmacotherapies, we now have supportive evidence for the use of percutaneous coronary intervention (PCI) in selected patients with ULM lesions and low to moderate SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) scores. [2] [3] [4] Aside from the use of drug-eluting stents (DES), there is no consensual agreement regarding the optimal PCI strategy for ULM stenosis, particularly when the distal bifurcation is involved. Moreover, few data are available on the treatment of in-stent restenosis (ISR) in this region. 5, 6 The aim of this study was to evaluate the optimal PCI strategy for patients with unprotected distal bifurcation left main coronary artery ISR following DES implantation (UDLM DES-ISR) and to determine whether the initial strategy affects the outcome of target lesion revascularization (TLR) for the ISR.
Methods
A retrospective cohort analysis was performed in consecutive patients with angiographic evidence of UDLM DES-ISR who underwent repeat PCI or CABG surgery between April 2002 and December 2008 in 3 high-volume centers (Milan, Italy, and Chiba, Japan) ( Figure 1 ). ULM disease was defined as a stenosis of at least 50% that involved the ostium, body, or distal segment of the left main coronary artery or within the proximal 5 mm of the left anterior descending coronary artery or left circumflex coronary artery (LCX) ostium. ULM lesions were divided into the following 2 groups: (1) ostium and body (nonbifurcation lesions) and (2) distal bifurcation (unprotected distal left main coronary artery [UDLM] ). Bifurcation lesions were classified according to the Medina classification 7 by 2 independent physicians. A true bifurcation lesion was defined as Medina class 1-1-1, 1-0-1, and 0-1-1. For the original procedure, a 1-stent strategy (1-SS) was defined as the use of a single stent, regardless of the lesion type. A 2-stent strategy (2-SS) was defined as the use of 2 stents, regardless of the technique used. This definition included the use of elective double-stent strategies, such as the mini-crush, crush, culotte, simultaneous kissing stenting, and V stenting, as well as scenarios where a second stent was necessary during a provisional T-stenting approach. In general, a 2-SS was selected when there was diffuse disease extending from the LCX ostium, whereas a 1-SS was preferred when there was only minimal or focal disease in this region. The antiplatelet regimens used were low-dose aspirin, which was recommended indefinitely, and a thienopyridine (ticlopidine 200-250 mg BID or clopidogrel 75 mg daily) for a minimum of 6 months after TLR.
Clinical data were collected by hospital visit or telephone contact at 6-month intervals. Angiographic follow-up was scheduled between 3 and 12 months or earlier if noninvasive evaluation or clinical presentation suggested the presence of ischemia. Additional angiography was performed in those patients with ambiguous ISR at follow-up angiography or when a patient presented with progressive anginal symptoms.
UDLM DES-ISR was defined as a luminal diameter stenosis of >50% within a DES or within 5 mm of the stent edges. The patterns of DES-ISR were classified as focal (Mehran ISR pattern I) or diffuse (Mehran ISR patterns II, III, IV) according to the geographic position of DES-ISR in relation to the previously implanted stent. 8 In the present study, multifocal DES-ISR (ie, both ostial left anterior descending coronary artery and ostial LCX) was considered as diffuse DES-ISR. Details of the pattern of disease and procedural strategy were obtained from procedural reports, visual assessment, or quantitative coronary angiographic measurement. Quantitative coronary angiographic assessment was performed by 3 independent investigators. TLR was defined as either PCI (plain old balloon angioplasty [POBA] or DES) or CABG performed to treat DES-ISR or stent thrombosis of the target lesion, including the proximal and distal edge segments of the stent, and the ostium of the side branches. The decision on the therapeutic strategy for UDLM DES-ISR was made after a discussion between the interventional cardiologist and the cardiac surgeon. POBA was defined as the use of compliant, semicompliant, or drug-eluting balloons without subsequent stent implantation. Treatment using DES included all patients who underwent stent implantation using a DES of any kind.
The primary end point of the study was a composite of major adverse cardiac events (MACE) defined as all-cause death, myocardial infarction (MI), and TLR. The secondary end points were the individual components of MACE. Death was considered cardiac in origin unless obvious noncardiac causes could be identified. MI was defined as the presence of pathological and new Q waves on an ECG or as an increase in creatine kinase-myocardial band level to >3 times the upper limit of normal. Stent thrombosis was defined according to Academic Research Consortium definitions. 9 Chronic kidney disease was defined as an estimated glomerular filtration rate of <60 mL/min per 1.73 m 2 , and severe chronic kidney disease was defined as an estimated glomerular filtration rate of <15 mL/min per 1.73 m 2 . 10 A European System for Cardiac Operative Risk Evaluation (EuroSCORE) of ≥6 was considered high operative risk. [11] [12] [13] A low SYNTAX score was defined as ≤22; an intermediate score, between 22 and 32; and a high score, ≥33, as described in the SYNTAX trial. 2 Continuous variables are expressed as mean±SD. Comparisons of clinical, echocardiographic, angiographic, or procedure-related characteristics of patients were performed by means of Student t test or Wilcoxon rank sum test (continuous variables) or χ 2 test (categorical) and on the basis of the distribution according to the type of TLR, original stent strategy, and ISR. Comparisons of event-free survival (Kaplan-Meier curves) were performed with the log-rank test. Cox regression analysis using purposeful selection of covariates 14 was performed to determine the independent predictors of a second TLR following repeat PCI, using predictors associated with second TLR (P<0.2) and those judged to be of clinical importance from previously published literature. To avoid overfitting, the number of independent variables entered into the final multivariable model was limited to a maximum of 1 for every 8 to 10 events. The results are reported as adjusted hazard ratios (HRs) with associated 95% CIs. All analyses were conducted using SPSS version 18.0 (SPSS Inc) software, and
WHAT IS KNOWN
• Unprotected left main coronary artery disease treated with drug-eluting stents, particularly lesions involving the distal bifurcation, may be complicated by restenosis.
• Limited data are available on the treatment of drugeluting stent in-stent restenosis in this high-risk lesion.
WHAT THE STUDY ADDS
• This study shows that isolated restenosis of the ostium of the left circumflex coronary artery is common and associated with an initial 2-stent strategy compared with a single stent.
• Whether the higher rates of in-stent restenosis following a 2-stent strategy are due to technique or disease complexity remains to be determined.
• Drug-eluting stents are more effective than balloon angioplasty for the treatment of unprotected distal left main coronary artery drug-eluting stent in-stent restenosis. 
Results
Between April 2002 and December 2008, 575 consecutive patients with de novo ULM stenosis were treated with DES implantation in 2 high-volume centers in Milan, Italy, and Chiba, Japan. Of these patients, we analyzed all 474 with stenosis involving the UDLM. Angiographic followup at ≥6 months was performed in 461 patients (80.1%) at a median of 246 days (interquartile range, 181-496 days). DES-ISR of ULM was identified in 99 patients (17.5%). DES-ISR occurred within the first year in 76 patients, between 1 and 2 years in 13 patients, between 2 and 3 years in 3 patients, and at ≥3 years in 7 patients. Of these, 7 patients had been treated for nonbifurcation ULM disease and 92 for complex disease involving the distal bifurcation ( Figure 1 ). In patients with bifurcation DES-ISR, 8 proceeded to CABG and the remaining 84 underwent repeat PCI (43 with POBA and 41 with further DES implantation).
Baseline clinical, lesion, and procedural characteristics of the 84 patients with UDLM DES-ISR treated with PCI are shown in Tables 1 and 2. The mean age was 65.5±9.5 years, 79.8% were men, and 46.4% had diabetes mellitus; 41.7% of patients underwent a 1-SS, and 58.3% underwent a 2-SS. A higher ejection fraction; use of a 2-SS; and focal DES-ISR, including ostial stenosis of LCX, were all more common in the POBA than in the DES group. By contrast, a history of MI, ULM disease with multivessel disease, and the use of an intraaortic balloon pump were more frequent in the DES group. Restenosis at the LCX ostium was found in 41 patients; 28 patients underwent PCI with POBA, and 13 underwent PCI with DES (P=0.19) ( Table 3 ).
Primary and Secondary End Points in Patients With UDLM DES-ISR Following PCI
Clinical follow-up data were available in all patients at 6 months and in 91.7% at 24 months (median, 24 months). Angiographic follow-up was obtained in 91.7%. Freedom from cardiac death plus MI, MACE, and TLR are shown in Figure 2 and Table 4 .
Major Adverse Cardiac Events
In the CABG group, MACE were observed in 1 patient who required TLR because of occlusion of the left internal mammary graft. There were no deaths or MI in the CABG group. In the PCI group, MACE during the follow-up period were seen in 31 patients. MACE were more frequently seen following POBA than following DES implantation (HR, 2.75; 95% CI, 1.26-5.98; P=0.01).
Cardiac Death and MI
Cardiac death occurred in 4 patients. Cardiac death and MI did not differ significantly according to the type of revascularization. Clinical and procedural characteristics of these 4 patients who had cardiac death are described in Table 5 . MI occurred in 2 patients.
Repeat TLR
A recurrent ISR requiring revascularization occurred in 28 patients overall. Repeat TLR following POBA was seen in 20 (47.6±7.7%) and was independent of the type or the location of DES-ISR (focal ISR group, 48.5±8.7%; diffuse ISR group, 44.4±16.6%). Repeat TLR following DES was seen in 8 (20.8±6.6%) and was again independent of the type and the location of DES-ISR (focal ISR group, 14.1±7.6%; diffuse ISR group, 28.8±11.0%). Even where ISR was focal, the use of a POBA strategy resulted in significantly more recurrence than the use of DES, irrespective of the original stenting strategy (HR, 4.14; 95% CI, 1.21-14.25; P=0.02). According to index restenosis type, the rates of repeat TLR were as follows: focal ISR, 35.2±6.5%; multifocal ISR, 66.7±19.2%; and diffuse ISR, 24.3±9.5%. These differences did not reach statistical significance probably because of the low number of patients. Overall, the original stent strategy was not predictive of recurrent DES-ISR. In many patients, a third PCI was performed because of clinical status, lesions not appropriate for CABG, or willingness of the patient to avoid surgery.
Predictors of Repeat TLR Following PCI in Patients With UDLM DES-ISR
On univariable analysis, estimated glomerular filtration rate, treatment with POBA, EuroSCORE >6, older age, high ejection fraction, and diabetes mellitus appeared to be associated with repeat TLR. Thereafter, 6 parameters with P<0.2 and 2 additional important parameters (the use of an initial 2-SS and focal versus diffuse disease) were included in the initial Cox regression analysis. On final Cox regression analysis, treatment with POBA and EuroSCORE >6 were the independent predictors of repeat TLR in patients who were treated with PCI ( Table 6 ).
Predictors of All-Cause Death in All Patients With UDLM DES-ISR
During the follow-up period, 7 patients died. To clarify the predictors of all-cause death, we analyzed all patients with UDLM-ISR (n=92). The univariable analysis showed that severe chronic kidney disease (HR, 16.60; P=0.01) and EuroSCORE >6 (HR, 18.75; P=0.001) were positive predictors.
Patients With Isolated DES-ISR Involving the LCX Ostium
UDLM DES-ISR was localized to the LCX ostium in 41 patients (44.6%). Only 9 of these patients (21.9%) presented with recurrent angina, with DES-ISR detected only at routine angiographic follow-up in the remaining 32 (78.1%). The size of the LCX (>3.0 mm) appeared to be associated with the symptoms in cases of restenosis (small LCX, 5.9%; large LCX, 30.4%; P=0.11). Despite the high incidence of DES-ISR in this region, there were no deaths in this patient subgroup up to at least 2 years. Additionally, recurrent DES-ISR was common in this subgroup, occurring in 15 patients (36.6±7.5%); 13 patients (46.4±9.4%) following treatment with POBA, and 2 patients (15.4±10.0%) following treatment with DES (HR, 3.75; 95% CI, 0.84-16.64; P=0.08). Lesions requiring a 2-SS were more complex compared to the ones treated with 1-SS (online-only Data Supplement  Table I ). These lesions had a higher incidence of ISR at the LCX ostium (HR, 2.51; 95% CI, 1.59-3.97; P=0.001) as well as a higher recurrent LCX-ISR (HR, 4.32; 95% CI, 0.97-19.20; P=0.054) following repeat PCI compared with a 1-SS (online-only Data Supplement Table II ).
Discussion
There are 3 important findings from this study. First, the data suggest that UDLM DES-ISR was associated with a lower incidence of MACE, driven by lower rates of TLR following additional DES implantation rather than by POBA. TLR following DES implantation was independent of the pattern of ISR (focal or diffuse). Second, focal and isolated restenosis of the LCX ostium is common, occurring in almost 40% of patients in the present series, and is likely to be associated with the use of a 2-SS for the initial procedure and with moresevere baseline lesion characteristics in these patients (onlineonly Data Supplement Table I ). However, the data raise questions regarding the clinical and prognostic significance of this phenomenon, with no cardiac death up to at least 2 years. Finally, the strategy used for the index procedure (1-SS versus 2-SS) might determine the risk of recurrent DES-ISR but only in the region of the LCX ostium. However, it remains to be established whether the mechanism of ISR in this region relates only to the stenting strategy or whether the pattern and complexity of disease in this region plays a role.
Is PCI With Repeat DES Implantation an Acceptable Treatment?
Consistent with previous reports, 5,6 the present data show that the treatment of UDLM DES-ISR with further DES is a safe and effective option, regardless of the restenosis pattern or the initial strategy. By contrast, treatment with POBA, even where DES-ISR is focal, results in suboptimal outcomes, with TLR rates exceeding 40% at 2 years. Although the cardiac mortality rate of 5% at 2 years reported in this study was slightly higher than in previous studies (1.7%-2.3%), 5, 6 it can be explained by the smaller number of patients with a high SYNTAX score (≥33) referred for CABG. Given that a EuroSCORE >6 and a history of severe chronic kidney disease were associated with all-cause death regardless of the TLR strategy, the present data support the concept that high-risk clinical patients have an increased risk of mortality. Furthermore, a higher EuroSCORE often reflects widespread atherosclerotic disease involving the peripheral and cerebral vasculature in addition to the coronary vessels; therefore, it is not surprising that restenotic disease is more aggressive and more common in these patients.
DES-ISR at the Ostial LCX
It has previously been reported that ISR at the LCX ostium following UDLM stenting is largely asymptomatic. 15 The present findings were consistent with this, with only 21.9% of patients presenting with recurrent angina and the majority detected only at follow-up angiography. Interestingly, no cardiac death was reported throughout the follow-up period (mean, 4.1 years), which might suggest that the long-term outcome of DES-ISR localized to this region is a benign phenomenon, especially when the LCX is small. Koo et al 16 used fractional flow reserve (FFR) to assess the functional significance of side-branch ostial compromise following provisional side-branch stenting of non-ULM lesions in 94 cases and performed a second FFR assessment after stenting. They found that the degree of side-branch compromise was overestimated angiographically compared with functional assessment. However, there is no consensual opinion regarding the accuracy and long-term outcome of FFR on focal lesions, either de novo or restenotic, at the ostial LCX because there often is a large discrepancy between physiological and anatomic assessment in this region. This has been shown in a small number of studies that have used simultaneous FFR and intravascular ultrasound to assess the significance of nonbifurcation and non-ULM restenotic lesions and found the correlation to be inconsistent. Kang et al 17 recently suggested new criteria for anatomic prediction of physiological lesion significance. They found that a minimal luminal area of >2.4 mm 2 could accurately exclude lesions with an FFR >0.8, although specificity was poor. However, this issue has yet to be addressed in UDLM disease and specifically in ISR lesions of the ostial LCX. Further studies involving longer-term follow-up of these lesions with FFR or intravascular ultrasound assessment are necessary to clarify prognosis and establish the need for treatment.
The Impact of the Initial Strategy on the Outcome of TLR With PCI
Consistent with previous reports, 4,18 complex lesions of UDLM disease requiring a 2-SS in the present series were associated with a higher repeat revascularization compared with lesions that could be treated with a 1-SS. Furthermore, although an initial 2-SS was not predictive of a total of recurrent ISR, a 2-SS was associated with a higher rate of recurrent LCX-ISR compared with a 1-SS. The characteristics of the lesions requiring a 2-SS were probably the prime factor, resulting in higher event rates at follow-up (online-only Data Supplement  Table I ). When necessary, a 2-SS can be justified, and may be preferable, provided that attempts are made to maximize stent expansion at the LCX ostium. 19, 20 Adjuvant intravascular imaging modalities, such as intravascular ultrasound or optical coherence tomography, may be useful to guide the diagnostic and interventional phases of the procedure to define optimal lesion management.
Limitations
The main limitation of this study is the relatively small cohort of patients and the lack of randomization. Furthermore, any major conclusion with P>0.01 could well be a false positive. In the present data, the number of patients treated with CABG for ULM-ISR was small. Therefore, to clarify the feasibility and efficacy of the TLR strategy in patients with ULM-ISR, more procedural experience, a longer-term follow-up period, and a larger patient population are needed to evaluate the role of CABG. Furthermore, although the pattern of ISR was not associated with development of recurrent ISR, a large sample size is needed to demonstrate the impact of ISR pattern on the recurrent ISR. Second, because the objective of this study was to correlate stent strategy with the development and pattern of ISR and to determine predictors of recurrent DES-ISR, we did not include patients with DES-ISR who were treated conservatively. Almost all patients in the study with >50% DES-ISR underwent revascularization, particularly in the earlier years. More recently, a physiological approach often is applied to the assessment and treatment of DES-ISR, particularly at the LCX ostium. No such physiological assessment was routinely performed in this study, with the result that recommendations for treatment of DES-ISR in this region must be taken in context. Third, although the use of different stent platforms and drugs are likely to influence the rate of ISR as well as the clinical outcomes, the majority of patients in the study received sirolimus-eluting or paclitaxel-eluting stents. Finally, the limited follow-up period did not enable us to make recommendations that additional DES implantation is safe and effective following UDLM DES-ISR, even at longer-term follow-up. However, it is likely that the emergence of new DES technologies will further improve safety and efficacy outcomes in the treatment of both de novo and ULM-ISR lesions.
Conclusions
This study suggests that patients with DES-ISR in the UDLM disease derive greater benefit from further DES implantation than from POBA alone, even if the restenosis is focal. Furthermore, complex lesions requiring a 2-SS were associated with a higher risk of initial LCX-ISR as well as recurrent LCX-ISR following repeat PCI. Finally, given that the majority of patients with focal LCX-ISR are asymptomatic, it remains to be seen whether these lesions, often found at follow-up angiography, should be treated. Further studies combining anatomic and physiological assessment, in addition to longer-term follow-up, are necessary to answer this important question.
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